Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWojciech JurczakGoethe University FrankfurtHZHeng ZhouMerck & Co., Inc., Rahway, NJ, USA (United States)NRNishitha ReddyMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Loading...

Member takes

Implication

Phase 2/3 trial shows promising efficacy and acceptable safety of zilovertamab vedotin in relapsed/refractory DLBCL, indicating potential as a new treatment option.

Key Points

  • To evaluate the efficacy and safety of zilovertamab vedotin plus standard therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
  • Participants aged ≥18 years with confirmed relapsed/refractory DLBCL were enrolled.
  • Received zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin for ≥6 cycles.
  • Primary endpoints included safety and the recommended phase 2 dose.
  • Overall response rates were 29.4% for ZV 1.5 mg/kg, 56.3% for ZV 1.75 mg/kg, and 42.9% for ZV 2.0 mg/kg.
  • Median overall survival was 11.5 months for ZV 1.5 mg/kg and 36.8 months for ZV 1.75 mg/kg.
  • Treatment-related adverse events occurred in 98% of participants, with the most common being diarrhea and neutropenia.

Cite This Study

Jurczak et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5d7https://doi.org/10.1182/blood-2025-3745
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-0072025 · 1 citations
  2. 2Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study2025 · 1 citations
  3. 3waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).2026
  4. 4Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study2025 · 1 citations
  5. 5Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025 · 7 citations